Neonatal News
-
Advances in Newborn SMA Screening research by SNP Biotechnology
BSD Robotics is proud to share a recent study conducted by SNP Biotechnology R&D Ltd “A new line method; A direct test in spinal muscular atrophy screening for DBS” now published in the journal of Molecular Genetics and Genomic Medicine. Given spinal muscular atrophy (SMA) is one of the most prevalent genetic disorders affecting young children and a major cause of death in ...
By BSD Robotics
-
Ony Biotech Prepares For The Future
Dr. James Cummings has been an unofficial member of the ONY Biotech family since 1989, when he first started working at the Children’s Hospital of Buffalo. This month, it becomes official, as Dr. Cummings joins the ONY Biotech team as Chief Medical Officer, and the founder of the company and former Chief Medical Officer, Dr. Edmund Egan, steps into the role of Chief Scientific Officer. ...
By ONY Biotech
-
Bayer receives positive CHMP opinion for Eylea in the EU for treatment of preterm infants with retinopathy of prematurity
Recommendation is based on the Phase III study FIREFLEYE and data from the follow-up study FIREFLEYE NEXT Retinopathy of prematurity (ROP) can lead to severe visual impairment and blindness Bayer will apply for a patent term extension for the patent covering aflibercept, the active ingredient in Eylea™, of six months once the European Commission adopts a decision for a label extension ...
By Bayer AG
-
Beyond Air® Reports Financial Results for the Second Quarter of Fiscal Year 2023
Beyond Air, Inc. (NASDAQ: XAIR) a medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, Ltd., ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced ...
-
Forge Biologics Announces Updated Positive Clinical Data in RESKUE, a Novel Phase 1/2 Gene Therapy Trial for Patients with Krabbe Disease
Clinical data demonstrating initial safety and efficacy from the RESKUE trial are being presented by Chief Medical Officer Maria Escolar, M.D., at the 29th Congress of European Society of Gene & Cell Therapy (ESGCT), October 11-14, 2022 Subjects treated with FBX-101 have shown increased galactocerebrosidase (GALC) enzyme activity in plasma and cerebrospinal fluid (CSF), normal white matter ...
-
Enalare Therapeutics Receives Orphan Drug Designation From the U.S. FDA on ENA-001 for the Treatment of Apnea of Prematurity (AoP)
ENA-001, a New Chemical Entity (NCE) with a novel mechanism of action as an agnostic respiratory stimulant, has previously been granted Rare Pediatric Disease designation for the Treatment of AoP by the FDA, with eligibility for a priority review voucher (PRV). The compound is also being developed by Enalare for the treatment of post-operative respiratory depression and community drug overdose. ...
-
Alfa Chemistry Offers High-Quality Dexmedetomidine Hydrochloride Meeting CP & EP Standards
Having established close cooperative relations with many pharmaceutical companies, universities, and research institutions, Alfa Chemistry decided to enlarge its active pharmaceutical ingredient (API) supply continuously in the hope of providing a more diversified product portfolio for customers. Fairly recently, the company announced the launch of dexmedetomidine hydrochloride, another API ...
-
Permanent laser hair removal technology
In recent years, with the rapid development of laser hair removal technology in medical beauty, laser beauty has become a new fashion in beauty. Some skin lesions that were difficult to cure or had poor curative effects in the past can now receive good curative effects. As one of the laser beauty treatments, permanent laser hair removal technology has gradually been recognized by patients with ...
-
Forge Reports Positive Clinical Data on Brain Development and Motor Function from the RESKUE Novel Phase 1/2 Gene Therapy Trial in Patients with Krabbe Disease at the SSIEM Annual Symposium
FBX-101 clinical data demonstrating safety and initial efficacy from the RESKUE trial is being presented at the 2022 Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium FBX-101 is a systemic AAV gene therapy following unrelated cord blood transplantation (“UCBT”) and has been well tolerated through Day 180 FBX-101 significantly increased GALC enzyme ...
-
Eagle Pharmaceuticals Takes Equity Stake in, with Option to Acquire, Enalare Therapeutics to Advance Global Development of ENA-001, a Novel Agnostic Respiratory Stimulant
ENA-001 is currently in development for: post-operative respiratory depression, community drug overdose, and Apnea of Prematurity Approval for post-operative respiratory depression expected in 2026 and community drug overdose thereafter ENA-001 works peripherally by inhibiting Big Potassium (BK) ion channels in the carotid bodies, which are located in the neck. By inhibiting these channels, ...
-
Incidence of traumatic lumbar punctures in neonates and infants
Our whitepaper takes a closer look at the lumbar puncture, the IQ-Tip system’s first indication, and presents the results that Injeq has obtained with the system. We discuss the various advantages that the system provides compared to a conventional spinal needle. You can download the white paper here: Clinical applications for the IQ-Tip system and their potential benefits ...
By Injeq Oy
-
Isabel Healthcare partners with Riverwood Healthcare to offer online symptom checker
Isabel Healthcare and Riverwood Healthcare have partnered to integrate Isabel’s AI symptom checker / self-triage platform into the Riverwood website to enhance care access and patient engagement. The symptom checker has been customized for Riverwood with integration of live chat and care option selection links and other pertinent content to help patients navigate to Riverwood care services ...
-
Enalare Therapeutics Receives Rare Pediatric Disease Designation for Lead Compound ENA-001 for the Treatment of Apnea of Prematurity
Enalare Therapeutics Inc., a biopharmaceutical company dedicated to developing novel therapies for patients suffering from life threatening critical care conditions, announced today that the Food and Drug Administration (FDA) has granted it's lead compound, ENA-001, rare pediatric disease designation for the treatment of Apnea of Prematurity. Enalare is planning to develop this unique agnostic ...
-
Proximie Partners with Jhpiego in New Initiative to Improve Obstetric Surgical Care
Proximie has teamed up with Jhpiego, a Johns Hopkins University affiliate, on a safe surgery project in Kenya to layer in their unique software that allows physicians anywhere in the world to virtually "scrub-in" and mentor colleagues in real time. Proximie has offered its technology to Jhpiego, a global health non-profit working in 40-plus countries, to improve obstetric surgical care for ...
-
Neonatal Incubator Developed By MOm And Eg Technology Achieves First Clinical Use In The UK
Created by mOm Founder & CEO, James Roberts, and developed by mOm & the engineering team at eg technology, this innovative, lightweight incubator helped to sustain a premature baby’s life at St Peter’s Hospital, Chertsey. The mOm incubator was originally conceived to save the lives of premature babies in challenging, low/middle-income settings; as well as provide more options ...
-
TriMedika showcases pioneering thermometer at MEDICA
TriMedika – an innovative medical technology manufacturer providing clinical devices for hospitals worldwide – is delighted to be joining the UK Pavilion at MEDICA 2021 (15 – 18 November 2021) to showcase their game-changing thermometer, designed to prevent cross-infection in hospitals. Founded in 2016, TriMedika manufactures the most accurate clinical devices for hospitals ...
By TriMedika
-
Isabel’s AI Engine to be Embedded in iCliniq`s Virtual Care Platform
Isabel Healthcare announced an agreement with iCliniq to integrate Isabel’s AI symptom checker / self-triage engine into the iCliniq’s Platform. iCliniq will utilize Isabel’s comprehensive API to embed the virtual triage engine into the consumer-facing workflows of their platform providing accurate and efficient self-triage engagement with users. As a global player in the ...
-
TriMedika Exhibit at MEDICA 2021
TriMedika, an innovative medical technology manufacturer providing clinical devices for hospitals worldwide – is delighted to be joining the ABHI UK Pavilion at MEDICA 2021 (15 – 18 November 2021) to showcase their game-changing thermometer, designed to prevent cross-infection in hospitals. Founded in 2016, TriMedika manufactures the most accurate clinical devices for hospitals ...
By TriMedika
-
Equine Today: The Importance of Having a Biosecurity Program at your Practice
Fluxergy’s is launching its environmental salmonella assay where equine practices and facilities can add in-house PCR testing to their biosecurity program. This avoids central lab processing and allows clinicians to clear stalls after simple overnight enrichment. Contact Sales What is Biosecurity? Biosecurity describes all the human actions that go into preventing disease in horses and ...
By Fluxergy
-
HemoShear Therapeutics Announces First Two Patients Dosed in Phase 2 Study of Oral Small Molecule HST5040 for Methylmalonic Acidemia (MMA) and Propionic Acidemia (PA)
HemoShear Therapeutics, Inc., a clinical stage company developing treatments for rare metabolic disorders, today announced that the first two patients have been dosed in the HERO (HElp Reduce Organic Acids) Phase 2 clinical trial of HST5040, an oral small molecule drug being investigated for the treatment of patients with methylmalonic acidemia (MMA) and propionic acidemia (PA). This trial seeks ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you